Jörg Schrader
Priv.-Doz. Dr. med.
Jörg Schrader
  • Facharzt für Innere Medizin
  • Facharzt für Gastroenterologie
  • 1.Arbeitsbereich
Deutsch (Muttersprache)







  • 2020
  • 2019
  • 2018
  • 2017
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2009
  • 2008
  • 2007
  • 2006
  • 2003
  • 2002

Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas
Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, Amin T, Viol F, Fehrle W, Dum D, Höflmayer D, Burandt E, Clauditz T, Perez D, Izbicki J, Wilczak W, Sauter G, Steurer S, Schrader J
ENDOCR PATHOL. 2020;31(2):182-189.

Bilateral Hematothorax without Hematemesis – an unusual Presentation of Variceal Bleeding
Paparoupa M, Schrader J, Jung C, Boenisch O, Lohse A, Kluge S
HEPATOLOGY. 2020 [Epub ahead of print].

Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors
Tatura M, Schmidt H, Haijat M, Stark M, Rinke A, Diels R, Lawlor R, Scarpa A, Schrader J, Hackert T, Schimmack S, Gress T, Buchholz M
NEUROENDOCRINOLOGY. 2020;110(1-2):23-34.

Pancreatitis due to pancreatic metastases of small bowel and lung neuroendocrine tumors
Reher D, Henes F, Clauditz T, Klutmann S, Izbicki J, Lohse A, Perez D, Schrader J
2019. ENETS Conference Programm. 73.

Response of the primary tumor in patients with pNETs treated with streptozotocin / 5-FU – a preliminary retrospective study
Reher D, Henes F, Gress T, Lohse A, Hörsch D, Cremer B, Rinke A, Schrader J
2019. 16th Annual ENETS Conference . 68.

Systemische Therapie bei neuroendokrinen Neoplasien des Darmes
Schrader J
Verdauungskrankheiten. 2019;37(1):17 - 24.

Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors
Schrader J, Henes F, Blaeker M, Zimmermann-Fraedrich K, Pace A, Perez D, Izbicki J, Lohse A, Benten D
ENDOCRINE. 2019;65(2):460-467.

S2k-Leitlinie Neuroendokrine Tumore

Z GASTROENTEROL. 2018;56(6):583-681.

The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance
Aristizabal Prada E, Spöttl G, Maurer J, Lauseker M, Koziolek E, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer C, Nölting S
ENDOCR-RELAT CANCER. 2018;25(10):893-908.

Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Benten D, Behrang Y, Unrau L, Weissmann V, Wolters-Eisfeld G, Burdak-Rothkamm S, Stahl F, Anlauf M, Grabowski P, Möbs M, Dieckhoff J, Sipos B, Fahl M, Eggers C, Perez D, Bockhorn M, Izbicki J, Lohse A, Schrader J
MOL CANCER RES. 2018;16(3):496-507.

HbA1c-basiertes Screening zur Erfassung eines unerkannten Diabetes mellitus bei gastroenterologischen Patienten in einer Klinik der Maximalversorgung
Fründt T, Schröder N, Pinnschmidt H, Hölzemer A, Heer J, Lohse A, Schrader J
Z GASTROENTEROL. 2018;56(08):e388-e389.

Loss of complex O-glycosylation impairs exocrine pancreatic function and induces MODY8-like diabetes in mice
Wolters-Eisfeld G, Mercanoglu B, Hofmann B, Wolpers T, Schnabel C, Harder S, Steffen P, Bachmann K, Steglich B, Schrader J, Gagliani N, Schlüter H, Güngör C, Izbicki J, Wagener C, Bockhorn M
EXP MOL MED. 2018;50(10):1-13.

Activation of the Akt-CREB signalling axis by a proline-rich heptapeptide confers resistance to stress-induced cell death and inflammation
Herkel J, Schrader J, Erez N, Lohse A, Cohen I
IMMUNOLOGY. 2017;151(4):474-480.

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours
Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon K, Cotoi C, Khan S, Cave J, Armstrong T, Weickert M, Izbicki J, Schrader J, Frilling A, Ramage J, Srirajaskanthan R
ENDOCR CONNECT. 2017;6(8):876-885.

Blood fibrinogen levels discriminate low- and high-risk intraductal papillary mucinous neoplasms (IPMNs)
Nentwich M, Menzel K, Reeh M, Uzunoglu F, Ghadban T, Bachmann K, Schrader J, Bockhorn M, Izbicki J, Perez D
EJSO-EUR J SURG ONC. 2017;43(4):758-762.

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer C, Aristizabal Prada E, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P
PLOS ONE. 2017;12(8):e0182852.

Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
Schrader J, Henes F, Perez D, Burdak-Rothkamm S, Stein A, Izbicki J, Lohse A
ANN ONCOL. 2017;28(4):904-905.

Synergistische Therapiewirkung der Kombination des Hsp90 Inhibitor AUY922 und des PI3K Inhibitors BYL719 mit Everolimus bei neuroendokrinen Tumoren
Weißmann V, Benten D, Wolters-Eisfeld G, Perez D, Izbicki J, Lohse A, Schrader J
Z GASTROENTEROL. 2017;55(08):KV 402.

Differential signaling by regulatory subunits of phosphoinositide-3-kinase influences cell survival in INS-1E insulinoma cells
Schrader J, Niebel P, Rossi A, Archontidou-Aprin E, Hörsch D
EXP CLIN ENDOCR DIAB. 2015;123(2):118-25.

Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo
Fallowfield J, Hayden A, Snowdon V, Aucott R, Stutchfield B, Mole D, Pellicoro A, Gordon-Walker T, Henke A, Schrader J, Trivedi P, Princivalle M, Forbes S, Collins J, Iredale J
HEPATOLOGY. 2014;59(4):1492-1504.

Molekulare Therapie neuroendokriner Neoplasien: Sunitinib (Sutent) und Everolimus (Afinetor).
Hörsch D, Schrader J
Verdauungskrankheiten. 2014;(32 (3)):147-150.

Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin
Wüstenberg A, Kah J, Singethan K, Sirma H, Keller A, Perez Rosal S, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse A, Tiegs G, Sass G
PLOS ONE. 2014;9(5):e96533.

The role of MDSCs in hepatocellular carcinoma--in vivo veritas?
Schrader J
J HEPATOL. 2013;59(5):921-3.

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K, Schrader J, Ittrich H, von Amsberg G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse A, Hörsch D, Brümmendorf T, Benten D
CLIN CANCER RES. 2012;18(17):4621-4632.

Pancreatic neuroendocrine neoplasms.
Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum R
Minerva Gastroenterol Dietol. 2012;58(4):401-426.

Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice.
Michailidou Z, Turban S, Miller E, Zou X, Schrader J, Ratcliffe P, Hadoke P, Walker B, Iredale J, Morton N, Seckl J
J BIOL CHEM. 2012;287(6):4188-4197.

Chronic liver inflammation dominated by interferon-γ can prevent hepatocarcinogenesis.
Schrader J, Herkel J
ONCOIMMUNOLOGY. 2012;1(2):222-223.

Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism.
Hay D, Pernagallo S, Diaz-Mochon J, Medine C, Greenhough S, Hannoun Z, Schrader J, Black J, Fletcher J, Dalgetty D, Thompson A, Newsome P, Forbes S, Ross J, Bradley M, Iredale J
STEM CELL RES. 2011;6(2):92-102.

Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis.
Lüth S, Schrader J, Zander S, Carambia A, Buchkremer J, Huber S, Reifenberg K, Yamamura K, Schirmacher P, Lohse A, Herkel J
CANCER RES. 2011;71(11):3763-3771.

Persistence of functional hepatocyte-like cells in immune-compromised mice.
Payne C, Samuel K, Anne P, King J, Brownstein D, Schrader J, Medine C, Forbes S, Iredale J, Newsome P, Hay D
LIVER INT. 2011;31(2):254-262.

Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.
Schrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S, Benten D, Forbes S, Wells R, Iredale J
HEPATOLOGY. 2011;53(4):1192-1205.

The inflammatory microenvironment of HCC - The plot becomes complex.
Schrader J, Iredale J
J HEPATOL. 2011.

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Balabanov M, Wege H, Moll J, Lohse A, Brümmendorf T
NEOPLASIA. 2009;11(9):934-944.

Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.
Huber S, Stahl F, Schrader J, Lüth S, Presser K, Carambia A, Flavell R, Werner S, Blessing M, Herkel J, Schramm C
J IMMUNOL. 2009;182(8):4633-4640.

Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown.
Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese J, Bacher M
BMC CANCER. 2009;9:464.

Senescence of activated stellate cells: not just early retirement.
Schrader J, Fallowfield J, Iredale J
HEPATOLOGY. 2009;49(3):1045-1047.

Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.
Schrader J, Sterneck M, Klose H, Lohse A, Nashan B, Fischer L

Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors
Grabowski P, Schrader J, Wagner J, Hörsch D, Arnold R, Arnold C, Georgieva I, Stein H, Zeitz M, Daniel P, Sturm I
CLIN CANCER RES. 2008;14(22):7378-84.

P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg.
Huber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, Lüth S, Blessing M, Herkel J, Schramm C
PLOS ONE. 2008;3(10):3302.

Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.
Sydow K, Mondon C, Schrader J, Konishi H, Cooke J
ARTERIOSCL THROM VAS. 2008;28(4):692-697.

Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Karhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch D, Hörsch D
NEUROENDOCRINOLOGY. 2007;85(1):45-53.

Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death.
Schrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel M, Hörsch D, Hofbauer L
Diabetologia. 2007;50(6):1243-1247.

Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells
Hofbauer L, Schrader J, Niebergall U, Viereck V, Burchert A, Hörsch D, Preissner K, Schoppet M
THROMB HAEMOSTASIS. 2006;95(4):708-14.

Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme
Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J
AM J PATHOL. 2003;162(1):11-7.

Human cytomegalovirus-mediated induction of MIF in fibroblasts
Bacher M, Eickmann M, Schrader J, Gemsa D, Heiske A
VIROLOGY. 2002;299(1):32-7.

Letzte Aktualisierung aus dem FIS: 04.12.2020 - 00:48 Uhr

Zertifikat - Assoziierte Klinik der Deutschen Leberstiftung 2020
European Reference Network for rare or low prevalence complex diseases //Network, Hepatological Diseases (ERN RARE-LIVER)
Logo SFB841 - Projekt: Leberentzündung: Infektion, Immunregulation und Konsequenzen
Logo KFO306 - Projekt: Primär Sklerosierende Cholangitis
Logo ENETS - European Neuroendocrine Tumor Society
Signet - Deutsche Gesellschaft für Infektiologie e.V.
Signet - Deutsches Zentrum für Infektionsforschung